This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Signal Transduction and Targeted Therapy Open Access 13 August 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Newsome, P. N. et al. A placebo-controlled trial of subcutaneous semaglutide in non-alcoholic steatohepatitis. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2028395 (2020)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dickson, I. Semaglutide is safe and efficacious for NASH resolution. Nat Rev Gastroenterol Hepatol 18, 6 (2021). https://doi.org/10.1038/s41575-020-00396-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-020-00396-z
This article is cited by
-
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Signal Transduction and Targeted Therapy (2022)